Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203164 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients
A Phase 3 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 254
- Enrollment target
- 6
- Study locations
NCT00203164: Completed Phase 3 study of Parkinson's Disease, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00203164 is a Phase 3 study of Parkinson's Disease that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 254 participants, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (60% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00203164, a Phase 3 study of Parkinson's Disease, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 254 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.
Primary Outcome
To evaluate the long-term safety and tolerability of rasagiline in PD patients with motor fluctuations treated with chronic levodopa/carbidopa (LD/CD) or levodopa/benserazide (LD/BZD) therapy
Conditions Studied
Interventions
- DRUG rasagiline mesylate
Study Locations (6)
New York
- Long Island Jewish Medical Center - New Hyde Park
- University of Rochester - Rochester
California
- Margolin Brain Institute - Fresno
Illinois
- Rush - Presbyterian St. Luke's Medical Center - Chicago
Nebraska
- Creighton University - Omaha
Pennsylvania
- Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2002-05 |
| Est. Completion | 2006-09 |
| Phase | Phase 3 |
What the finished NCT00203164 record still lists
NCT00203164 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 634-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Parkinson's Disease appearing as the primary indexed condition, and to 1 intervention - of which rasagiline mesylate is the first listed.
NCT00203164 lists 6 locations in 5 states (New York, California, Illinois).
Frequently Asked Questions
What is clinical trial NCT00203164 about?
NCT00203164 is a clinical study titled "Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients". This is a study to look at the effectiveness, tolerability, and safety of one dose of rasagiline in advanced Parkinson's disease (PD) patients who have been treated with Levodopa/Carbidopa therapy.
What is the current status of trial NCT00203164?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 254 participants. The study started on 2002-05. Estimated completion is 2006-09.
What conditions does trial NCT00203164 study?
This clinical trial studies the following conditions: Parkinson's Disease.
What interventions are being tested in trial NCT00203164?
The interventions under investigation include: rasagiline mesylate (DRUG).
Who is sponsoring clinical trial NCT00203164?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00203164 being conducted?
This trial has 6 study locations across California, Illinois, Nebraska, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00203164's enrollment target sits among peer trials
254 29th of 158 higher than 130 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
RECRUITING · Phase 3
-
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
ACTIVE NOT RECRUITING · Phase 3
-
Deep Brain Stimulation for Parkinson's Disease Trial
COMPLETED · Phase 3
-
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
COMPLETED · Phase 3
-
Study of KW-6002 (Istradefylline) in Parkinson's Disease in Patients With Motor Response Complications on Levodopa
COMPLETED · Phase 3
-
An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia